Concepedia

Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule

Mitch A. Phelps, Darlene M. Rozewski, Jeffrey S. Johnston, Katherine L. Farley, Katie A. Albanese, John C. Byrd, Thomas S. Lin, Michael R. Grever, James T. Dalton

Journal of Chromatography B · 2008 · 17 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo

Sheng‐Hao Chao, David H. Price · Journal of Biological Chemistry · 2001 · 638 citations · Full text

, , +14

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Bradley A. Carlson, M M Dubay, Edward A. Sausville et al. · PubMed · 1996 · 537 citations

, , +14

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson et al. · Journal of Clinical Oncology · 1998 · 408 citations

, , +15

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

John C. Byrd, Thomas S. Lin, James T. Dalton et al. · Blood · 2006 · 388 citations · Full text

, , +7

Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275

Michael D. Losiewicz, B. A. Carlson, Gurmeet Kaur et al. · Biochemical and Biophysical Research Communications · 1994 · 346 citations

, , +15